Actualités

While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.

Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.

ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

AbbVie and Baxter both flashed the same bullish technical signal this month, but one golden cross signals genuine momentum while the other masks a fundamentally broken business. Knowing which is which could protect your retirement income from a costly mistake.

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.11% and +0.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AbbVie stock has delivered a strong 151.6% return over the past five years, yet there is a clear split on valuation. A Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount, while earnings based multiples suggest the shares trade on the rich side. AbbVie’s 151.6% gain over five years puts long term holders in a strong position. This can make fresh entry points and future returns more sensitive to what you pay today. Expectations around newer immunology and oncology...

AbbVie, Enbridge, and Coca-Cola pay high dividends and are the types of stocks that investors can buy and forget about.

An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison.

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.

The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.

According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.

Drug pricing matters, but pipelines matter even more.

At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.

Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the ... The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.

HSBC Picks 10 Stocks to Watch as Earnings Season Begins

West Pharmaceutical Services (NYSE:WST) has sold the rights and facilities related to its SmartDose 3.5 mL On Body Delivery System to AbbVie. The transaction shifts ownership of this specific large volume wearable injector platform while allowing West Pharmaceutical Services to focus on other drug delivery offerings. The deal reflects a change in how NYSE:WST is positioning its portfolio within the drug delivery and pharmaceutical packaging market. West Pharmaceutical Services operates in...

JNJ and AbbVie both beat revenue expectations in Q1 2026, yet their strategies could not look more different, and which playbook actually wins depends entirely on what kind of investor you are.

This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.

Big pharma is funding a field it once dismissed. These three psychedelic stocks carry possible clinical catalysts as the healthcare industry turns to alternative medicines.

In the closing of the recent trading day, AbbVie (ABBV) stood at $249.91, denoting a -1.12% move from the preceding trading day.

Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.

AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.

West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.

FTSE 100 Live pre-open Blue-chip stocks in London and mainland Europe are set to rebound on Thursday after reports that the US and Iran could agree a new ceasefire deal. FTSE 100 futures pointed to a gain of 36 points, a day after the index plunged almost 177 points to end...

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri